• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Senza categoria

19 May 2020

Qinlock (ripretinib) is the First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors


by Elixi

11 May 2020

Novartis announces FDA approval of MET inhibitor Tabrecta (capmatinib)for metastatic non-small cell lung cancer with METex14


by Elixi

27 April 2020

MenQuadfi is Sanofi’s Latest vaccine for the prevention of invasive meningococcal disease (MenACWY)


by Elixi

18 April 2020

Tukysa (tucatinib) new option of treatment of adult patients with advanced forms of HER2-positive breast cancer


by Elixi

13 April 2020

Koselugo (selumetinib), newly approved treatment of neurofibromatosis type 1 (NF1)


by Elixi

3 March 2020

Sarclisa (isatuximab-irfc), new Therapy for Patients with Previously Treated Multiple Myeloma


by Elixi

28 February 2020

Ofatumumab, the new potential first-choice treatment for Relapsing forms of Multiple Sclerosis


by Elixi

22 February 2020

FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome


by Elixi

11 February 2020

FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma


by Elixi

9 February 2020

First Cardiac Ultrasound Software That Uses Artificial Intelligence to Guide User


by Elixi

  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13